NovoCure (NASDAQ: NVCR) CFO logs tax sale and new equity grants

Rhea-AI Filing Summary

NovoCure Ltd Chief Financial Officer Christoph Brackmann reported a mix of equity grants and a small mandated share sale. He received 55,137 ordinary shares as a restricted stock award, which are scheduled to vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment.

He was also granted options over 80,674 ordinary shares, vesting in equal parts on the first through fourth anniversaries, subject to continued employment. In connection with restricted stock unit vesting, he sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement, leaving 182,842 ordinary shares held directly afterward.

Insider Trade Summary

Net Seller: 6,412 shares ($85,314)

Net Sell 3 txns

Insider Brackmann Christoph

Role Chief Financial Officer

Sold 6,412 shs ($85K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	6,412	$13.3054	$85K
Grant/Award	Stock Option (Right to Buy)	80,674	$0.00	--
Grant/Award	Ordinary Shares	55,137	$0.00	--

Holdings After Transaction: Ordinary Shares — 182,842 shares (Direct); Stock Option (Right to Buy) — 80,674 shares (Direct)

Footnotes (1)

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brackmann Christoph

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		A		55,137	A	$0.00	189,254	D
Ordinary Shares	03/04/2026		S		6,412(2)	D	$13.3054(3)	182,842	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.3	03/03/2026		A		80,674		(4)	03/03/2036	Ordinary Shares	80,674	$0.00	80,674	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

3. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.

4. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Remarks:

	Steven Robbins, as attorney in fact for Brackmann, Christoph	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NovoCure (NVCR) CFO Christoph Brackmann report?

He reported new equity awards and a tax-related sale. Brackmann received 55,137 ordinary shares as restricted stock units and options over 80,674 shares, and sold 6,412 ordinary shares in a mandated transaction to cover tax withholding obligations tied to vesting.

How many NovoCure (NVCR) shares did the CFO sell and at what price?

He sold 6,412 ordinary shares. The weighted average sale price was $13.3054 per share, executed in multiple trades between $13.21 and $13.445. The sale was required to satisfy tax withholding obligations under the company’s sell-to-cover equity award arrangements.

Were the NovoCure CFO’s share sales discretionary trading activity?

The sale was not discretionary trading. The 6,412 shares were sold under a mandated “sell to cover” provision in NovoCure’s equity incentive award agreement, solely to fund tax withholding when restricted stock units vested, rather than as an elective open-market divestment decision.

What restricted stock awards did NovoCure (NVCR) grant its CFO?

He received 55,137 ordinary shares as restricted stock units. These units are scheduled to vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent on his continued employment with NovoCure through each respective vesting date.

What stock options did NovoCure (NVCR) grant to its CFO?

NovoCure granted options over 80,674 ordinary shares. These options vest in four equal parts on the first, second, third, and fourth anniversaries of the grant date, with each vesting tranche conditioned on Christoph Brackmann’s continued employment through the applicable vesting anniversary.

How many NovoCure ordinary shares does the CFO hold after these transactions?

After the tax-related sale, he directly holds 182,842 ordinary shares. This figure reflects his ownership following the disposition of 6,412 shares to cover tax withholding and the separate acquisition of restricted stock units and stock options reported in the same Form 4 filing.